Working in strategic collaboration with John Hopkins Medicine for the improvement of education and quality, our hospital provides services in all branches including in particular, oncologic sciences, cardiovascular health, gynecology and IVF, neurological sciences, surgical sciences, internal medicine, diagnosis and imaging.
So,
PSMA-targeted therapy is a newer type of radiation therapy that healthcare providers use to treat prostate cancer. Your provider may recommend this treatment if you don’t respond to other prostate cancer treatments or if your prostate cancer spreads to other areas of your body.
H
Happy Patient
Treatments in specifics
Lutetium-177 PSMA Therapy, also called Prostate-Specific Membrane Antigen Therapy, is a popular treatment choice for men experiencing advanced prostate cancer with metastatic or treatment-resistant prostate tumours.
In many patients, the treatment has proven to be a successful way to reduce the size of the tumours. Men who have undergone radical prostatectomy or primary radiotherapy but show symptoms of metastatic recurrence may find Lutetium-177 PSMA Therapy a viable treatment option. The therapy has proved effective at reducing the size of tumors and preventing their further growth. The treatment is not yet part of routine clinical care; yet in many patients, the therapy has been able to achieve long-term remission.
Day #1 –
arrival to Turkey, airport pick-up, transfer to the hotel
Day#2 –
Blood tests,
Kidney Scintigraphy (generally done only on the first visit)
PSMA PET/CT (if necessary)
Nuclear Medicine Examination w/ Dr. Kezban Berberoglu
Day#3 – Lu-177 Treatment
Day#4 –
Post-treatment scan
Evaluation of results w/ Dr. Kezban Berberoglu
**Generally lutetium patients can fly back 2-3 days after the treatment.
Treatments in specifics
Are you searching for the latest treatment options for Metastatic castration-resistant prostate cancer?
Prostate cancer is the second most common cancer diagnosed in the World today. More men die from complications associated with prostate cancer and metastatic castration-resistant prostate cancer (mCRPC) than with lung cancer.
The FDA-approved recently approved Actinium-225 PSMA therapy that uses radiolabelled monoclonal antibodies to target PSMA-positive tumours. In contrast to conventional external beam radiotherapy where the whole organ or at least a big part of the organ is exposed, the Ac-225 PSMA therapy allows doctors to deliver radiation directly to the tumour without affecting the nearby tissues. This therapy is recommended for patients who cannot tolerate other treatments or whose disease progresses even after receiving all other kinds of therapies. It can also treat patients with bone metastases, lymph node involvement, or visceral metastases.
According to a research study conducted by the University of Texas MD Anderson Cancer Center. Patients who had failed previous hormone therapy were randomly assigned to receive either Ac-225 PSMA or a placebo. After six months, the researchers found that patients receiving Actinium-225 PSMA showed significantly improved overall survival compared with those who received a placebo.
Day #1 –
arrival to Turkey, airport pick-up, transfer to the hotel
Day#2 –
Blood tests,
Kidney Scintigraphy (generally done only on the first visit)
PSMA PET/CT (if necessary)
Nuclear Medicine Examination w/ Dr. Kezban Berberoglu
Day#3 – Ac-225 Treatment
**Generally actinium patients can fly back one day after the treatment.
